Skip to main content
. 2018 Aug 23;36(29):2926–2934. doi: 10.1200/JCO.2018.77.7250

Fig A3.

Fig A3.

Disease-free survival (DFS) and overall survival (OS) by early response status. (A) Rapid early responders: 5-year DFS was 93.3% (89.4% to 97.1%) for Capizzi-style escalating intravenous methotrexate (C-MTX) versus 90.0% (85.1% to 94.6%) for high-dose methotrexate (HDMTX; hazard ratio, 0.722 [0.421 to 1.238]; P = .23), and OS was 94.5% (91.0% to 98.0%) for C-MTX versus 92.1% (87.8% to 96.4%) for HDMTX (hazard ratio, 0.801 [0.429 to 1.493]; P = .48). (B) Slow early responders: 5-year DFS was 88.7% (82.7% to 94.7%) for C-MTX versus 78.1% (70.4% to 85.8%) for HDMTX (hazard ratio, 0.501 [0.305 to 0.824]; P = .001), and OS was 92.4% (87.3% to 97.5%) for C-MTX versus 85.2% (78.6% to 91.8%) with HDMTX (hazard ratio, 0.506 [0.276 to 0.928]; P = .03).